T reatment of life-threatening hypercalcemia (serum calcium level greater than 3.25 mmol/L)
is ideally directed at the primary cause (usually malignant disease or hyperparathyroi …

No satisfactory medical therapy exists for the treatment of primary hyperparathyroidism.
Calcitonin and diphosphonates do not give good long‐term control. This work examines the …

Background. Recent studies suggest a role for somatostatin in the medical treatment of
hyperparathyroidism. In a prospective, randomized, controlled, triple blinded clinical trial in …

Somatostatin (SRIF) is effective in the non-operative management of a variety endocrine
tumors. A potential role of SRIF for treatment of patients with primary hyperparathyroidism …

We describe the successful treatment with octreotide, a somatostatin analogue, of a patient
with malignant hypercalcemia associated with advanced breast cancer. A 70-year-old …

In this review, the efficacy of bisphosphonates for the control of endocrine-and malignancy-
related hypercalcemia is addressed. The bisphosphonates are an important group of bone …

We have studied seven subjects with medullary thyroid carcinoma. Each had elevated basal
serum calcitonin (CT) levels following total thyroidectomy. After subcutaneous administration …

The management of hypercalcemia of malignancy (HCM) is difficult if the underlying
neoplasm cannot be treated successfully. The overexpression of parathyroid hormone …

Although receptors for somatostatin are found in bone cells, the effect of somatostatin
analogs on calcium metabolism is unknown. The authors studied, in a metabolic ward, the …

To combine the rapid hypocalcemic effects of calcitonin with the delayed effects of
pamidronate, a combination of a single dose of pamidronate and serial doses of eel …